Anti-BACE1 has been reported to be highly selective and does not inhibit the related enzymes BACE2 or cathepsin D. Thus, BACE1 can be targeted in a highly selective manner through passive immunization with anti-BACE1, providing another potential approach for treating AD (Atwal et al., 2011). Here, BACE1 is linked to Alzheimer disease.